Drug updated on 9/4/2024
Dosage Form | Capsule (oral; 20 mg, 80 mg) |
Drug Class | Kinase inhibitors |
Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated for the treatment of patients with progressive, metastatic medullary thyroid cancer.
Latest News
Summary
- Cometriq (cabozantinib) is indicated for the treatment of patients with progressive, metastatic medullary thyroid cancer.
- This summary is based on the review of 10 systematic review(s)/meta-analysis(es). [1-10]
- Metastatic Merkel Cell Carcinoma (MCC) and Medullary Thyroid Carcinoma (MTC): Cabozantinib effectively controlled MCC and MTC in an 83-year-old immunosuppressed male, with no MCC relapse after 24 months of treatment.
- Glucose and Lipid Metabolism in Thyroid Malignancies: Cabozantinib was associated with elevated glucose levels (prevalence: 1-17%), hypercholesterolemia (prevalence: 4-40%), and hypertriglyceridemia (prevalence: 1-86%).
- Renal Cell Carcinoma (RCC), Castration-Resistant Prostate Cancer (CRPC), Non-Small Cell Lung Cancer (NSCLC): Cabozantinib in combination therapy showed improved progression-free survival (PFS) compared to standard treatments.
- Radioiodine-Refractory Differentiated Thyroid Cancer (RAIR-DTC): Cabozantinib significantly improved PFS compared to placebo, though the effect size was not specified.
- Cabozantinib was associated with metabolic alterations, including elevated glucose levels and hyperlipidemia, potentially leading to severe, life-threatening events.
- Grade 3 or higher adverse events occurred in 48.5% of patients with medullary thyroid carcinoma (MTC) treated with TKIs, and 44.7% discontinued treatment due to these adverse events.
- Most patients with thyroid cancer experienced adverse effects, with substantial impact on the management of long-term outcomes.
- There is no population types or subgroups information available in the reviewed studies.
Product Monograph / Prescribing Information
Document Title | Year | Source |
---|---|---|
Cometriq (cabozantinib) Prescribing Information. | 2020 | Exelixis, Inc. Alameda, CA |
Systematic Reviews / Meta-Analyses
Clinical Practice Guidelines
Document Title | Year | Source |
---|---|---|
Guidelines on the use of systemic therapy in patients with advanced thyroid cancer. | 2023 | Clinical Oncology |
Essential news for clinical practice—thyroid cancer. | 2023 | Magazine of European Medical Oncology |
Clinical utility of cabozantinib in the treatment of locally advanced or metastatic differentiated thyroid carcinoma: patient selection and reported outcomes. | 2023 | Management and Research |
AGA clinical practice guideline on systemic therapy for hepatocellular carcinoma. | 2022 | Gastroenterology |
ESMO Clinical Practice Guideline update on the use of systemic therapy in advanced thyroid cancer. | 2022 | Annals of Oncology |
Thyroid carcinoma, version 2.2022, NCCN clinical practice guidelines in oncology. | 2022 | Journal of National Comprehensive Cancer Network |
Current guidelines for management of medullary thyroid carcinoma. | 2021 | Endocrinology and Metabolsim |
Thyroid cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. | 2019 | Annals of Oncology |